Progerinin ( DrugBank: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
191	ウェルナー症候群	1
333	ハッチンソン・ギルフォード症候群	1

191. ウェルナー症候群

臨床試験数 : 3 / 薬物数 : 4 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 5

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04512963 (ClinicalTrials.gov)	August 24, 2020	6/8/2020	Phase I Study of Progerinin in Healthy Volunteers	A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study Including a Food Interaction Study, Followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of Progerinin in Healthy Volunteers	Hutchinson-Gilford Progeria Syndrome;Werner Syndrome	Drug: Progerinin;Drug: Placebo	PRG Science & Technology Co., Ltd.	Amarex Clinical Research	Completed	18 Years	45 Years	All	64	Phase 1	United States

333. ハッチンソン・ギルフォード症候群

臨床試験数 : 7 / 薬物数 : 8 - (DrugBank : 3) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 6

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04512963 (ClinicalTrials.gov)	August 24, 2020	6/8/2020	Phase I Study of Progerinin in Healthy Volunteers	A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study Including a Food Interaction Study, Followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of Progerinin in Healthy Volunteers	Hutchinson-Gilford Progeria Syndrome;Werner Syndrome	Drug: Progerinin;Drug: Placebo	PRG Science & Technology Co., Ltd.	Amarex Clinical Research	Completed	18 Years	45 Years	All	64	Phase 1	United States